- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02778542
Bidirectional Text Messaging for Measurement and Motivation of Medication Adherence in Hypertension, a Pilot Study (Way2Text)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System and offered remote monitoring with electronic pill bottles or bidirectional text messaging. Our aim is to analyze and compare the effects of remote monitoring with electronic pill bottles versus bidirectional messaging on blood pressure reduction after 4 months.
Patients will be randomized 2:2:1 to Arm A (electronic pill bottle), Arm B (bidirectional messaging), and Arm C (usual care). A total of 150 participants will be enrolled in the study, with 60 in each intervention arm and 30 in the control. After 4 months all patients will complete an in-person follow-up blood pressure measurement and end of program survey. We will monitor all patient's medical records for an additional 8 months after the intervention to track blood pressure measurement and number of outpatient visits.
Accrual: Participants in this study will be patients being treated within the UPHS health system. They will be identified via daily electronic medical records review by our study staff. The study staff will work with UPHS to create a filter for the electronic medical record system that will generate a monthly list of patients who may meet the study criteria. A study coordinator will review the list of patients to determine eligibility. If patients meet the minimal requirements they will be added to the study screening data base and contacted via recruitment letter and up to 3 follow-up phone calls. The intervention of the study will be 4 months from date of consent, and an additional 8 months of follow-up, passively monitoring visit utilization and blood pressure in the electronic medical record. After a patient enrolls a message will be sent to their PCP via EPIC to notify their physician that their patient is enrolled in our study. At the conclusion of the intervention, participants will complete an in-person blood pressure measurement and post-study survey. Information about BP measurements will be recorded in EPIC and message will be sent to the PCP with the research BP measurement included.
Analysis Plan: The primary outcome will be the systolic blood pressure during the 4 month visit, controlling for the initial systolic blood pressure. Additional outcomes include, percent that are normotensive, recruitment and attrition rates, and patient perceptions about intervention from survey. We will also track BP measurements from the EMR that is obtained through usual care as well as utilization of PCP visits, MPM messaging, and phone calls. We will also compare medication adherence between patients with the electron pill bottles and the patients with bidirectional messaging. Assuming 5.3mmHg standard deviation of SBP (given variability of BP over time) and a two-sided significance level of 0.017 (to accommodate the three pairwise comparisons), our sample size of 60 in each intervention arm and 30 in the control arm provides 80% power to detect a difference in SBP reduction of 3.75 mmHg between either intervention and usual care, and a difference in SBP reduction of 3.1 mmHg between the electronic pill bottle and bidirectional text messaging arms.
Data Safety: Paper-based records will be kept in a secure location and only be accessible to personnel involved in the study. Computer-based files will only be made available to personnel involved in the study through the use of access privileges and passwords.
Prior to access to any study-related information, personnel will be required to sign statements agreeing to protect the security and confidentiality of identifiable information.
Wherever feasible, identifiers will be removed from study-related information. Precautions are in place to ensure the data is secure by using passwords and encryption, because the research involves web-based surveys.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Hypertension patients aged 18-75
- At least two clinic visits in the past 12 months
- Blood pressure readings in the last two visits that exceed recommended guidelines (150/90 or 140/90 if aged 21-59 yrs. or with diabetes or nondiabetic CKD).
- Cellular phone with text messaging capabilities
- Prescribed at least one medication for hypertension
Exclusion Criteria:
- Will not or cannot give consent
- Diagnosed with dementia, end stage renal disease, cirrhosis, or metastatic cancer
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Electronic Pill Bottle
Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data.
Participants will also receive a daily text message reminder to take your blood pressure medication.
|
Patients receive electronic pill bottle for their blood pressure medication.
Study team can monitor pill bottle openings.
Patients also receive daily text reminders to take their blood pressure medication.
|
Aktiver Komparator: Bidirectional Text Messaging
Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication.
Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
|
Patients receive daily text reminders to take their blood pressure medication.
Patients are asked to text their adherence daily.
|
Kein Eingriff: Usual Care
Participants in this arm do not receive a medication reminder system.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Systolic blood pressure
Zeitfenster: after 4 month intervention
|
The primary outcome will be the systolic blood pressure during the 4 month in-person visit, controlling for the initial systolic blood pressure
|
after 4 month intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Medication Adherence
Zeitfenster: 4 month intervention
|
We will compare medication adherence between patients with the electronic pill bottles and the patients with bidirectional messaging.
|
4 month intervention
|
Passive EMR monitoring
Zeitfenster: 12 months, including 4 months of intervention and 8 months after intervention
|
We will also track BP measurements from the EMR that is obtained through usual care as well as utilization of PCP visits, MPM messaging, and phone calls.
|
12 months, including 4 months of intervention and 8 months after intervention
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 824815
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hypertonie
-
Nantes University HospitalBeendetZirrhotischer Patient mit Verdacht auf portale Hypertension und im Rahmen eines OV-ScreeningsFrankreich
Klinische Studien zur Electronic Pill Bottle
-
NYU Langone HealthAbgeschlossen
-
Manan ShuklaAbgeschlossenAsthma | Chronische ErkrankungVereinigte Staaten
-
The University of Texas Health Science Center,...National Cancer Institute (NCI); Fox Chase Cancer Center; University of Kansas; New... und andere MitarbeiterNoch keine RekrutierungKopf-Hals-KrebsVereinigte Staaten
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)RekrutierungDepressive Symptome | Koronare HerzerkrankungVereinigte Staaten
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRekrutierungBrustkrebs | DarmkrebsKanada
-
Ad scientiamAbgeschlossen
-
China Medical University HospitalAbgeschlossen
-
University of PittsburghZurückgezogenMedikamentenhaftung | Nebenwirkung auf das Medikament | Nichteinhaltung von MedikamentenVereinigte Staaten
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Aktiv, nicht rekrutierendBlutdruck | MedikamentenhaftungVereinigte Staaten
-
University of California, San FranciscoNoch keine RekrutierungMagen-Darm-Krebs | Magen-Darm-Krebs mit MetastasenVereinigte Staaten